医学
免疫疗法
叶酸受体
单克隆抗体
靶向治疗
肺癌
癌症
癌症研究
伴生诊断
卵巢癌
内科学
生物信息学
肿瘤科
乳腺癌
免疫学
抗体
癌细胞
生物
作者
Anthony Cheung,Heather J. Bax,Debra H. Josephs,Kristina M. Ilieva,Giulia Pellizzari,James W. Opzoomer,Jacinta Bloomfield,Matthew Fittall,Anita Grigoriadis,Mariangela Figini,Silvana Canevari,James Spicer,Andrew Tutt,Sophia N. Karagiannis
出处
期刊:Oncotarget
[Impact Journals, LLC]
日期:2016-05-27
卷期号:7 (32): 52553-52574
被引量:303
标识
DOI:10.18632/oncotarget.9651
摘要
Promising targeted treatments and immunotherapy strategies in oncology and advancements in our understanding of molecular pathways that underpin cancer development have reignited interest in the tumor-associated antigen Folate Receptor alpha (FRα). FRα is a glycosylphosphatidylinositol (GPI)-anchored membrane protein. Its overexpression in tumors such as ovarian, breast and lung cancers, low and restricted distribution in normal tissues, alongside emerging insights into tumor-promoting functions and association of expression with patient prognosis, together render FRα an attractive therapeutic target. In this review, we summarize the role of FRα in cancer development, we consider FRα as a potential diagnostic and prognostic tool, and we discuss different targeted treatment approaches with a specific focus on monoclonal antibodies. Renewed attention to FRα may point to novel individualized treatment approaches to improve the clinical management of patient groups that do not adequately benefit from current conventional therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI